Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte
This review evaluates TPM203, a novel nanoparticle-based therapy for Pemphigus Vulgaris, detailing its safety profile, rapid pharmacokinetics, and ability to modulate regulatory T-cell and memory B-cell populations to induce immune toleranc
This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients
The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability
This report examines a clinical trial using 30-minute daily saturated saline immersion to treat refractory plantar warts, achieving an 88.2% complete remission rate without pain or recurrence.
The Phase 3 DISCREET trial demonstrates that apremilast provides sustained clinical efficacy and quality-of-life improvements for patients with moderate to severe genital psoriasis over 32 weeks, offering a viable oral alternative for a tra
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
A pragmatic RCT comparing weekly versus daily bathing in 438 eczema patients found no significant difference in symptom severity, supporting patient autonomy in choosing hygiene routines.
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.
This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps
Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin
This review synthesizes findings from the CLEAN-IT trial and historical data to evaluate the impact of chlorhexidine bathing on nosocomial infections, MDR pathogens, and reserve antibiotic consumption in critically ill patients.
The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient
Open language-specific specialty feeds and department pages.